BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
152.7 ^USD	-2.22%		-11.65%	-15.33%

May. 24	BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	MT
May. 24	BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	CI

BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024

May 08, 2024 at 06:00 am EDT

BeiGene, Ltd. anticipated opening of biologics manufacturing facility and clinical R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024.

Latest news about BeiGene, Ltd.

BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	May. 24	MT
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	May. 24	CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	May. 21	MT
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	May. 14	CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	May. 08	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08	MT
BeiGene's Q1 Loss Narrows as Revenue Rises	May. 08	MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M	May. 08	MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	May. 08	CI
Amgen Posts Higher 1Q Revenue, Swings to Loss	May. 02	DJ
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23	MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	Apr. 23	DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	Apr. 23	MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	CI
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
BeiGene, Ltd. Announces Executive Changes	Mar. 20	CI

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract No:2610

More about the company

Income Statement Evolution

More financial data

Ratings for BeiGene, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

152.7 USD

Average target price

267 USD

Spread / Average Target

+74.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BEIGENE, LTD.	-15.33%	15.97B
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B
LEGEND BIOTECH CORPORATION	-31.18%	7.55B

Bio Therapeutic Drugs

BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024

Latest news about BeiGene, Ltd.

Chart BeiGene, Ltd.

Company Profile

Income Statement Evolution

Ratings for BeiGene, Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs